Drug Trial Radar · NCT05749588
FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Mar 30, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.
Conditions
- Triple-negative Breast Cancer
Interventions
A1: SHR-A1811Drug
A1: an anti-HER2 antibody-drug conjugate (ADC)
A2: SHR-A1811 with Camrelizumab with famitinibDrug
A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) Camrelizumab: an anti-programmed death-1 (PD-1) antibody
B1: TROP2 ADCDrug
B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
B2: TROP2 ADC with CamrelizumabDrug
B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC Camrelizumab: an anti-programmed death-1 (PD-1) antibody
C1: SHR-A1811Drug
C1: an anti-HER2 antibody-drug conjugate (ADC)
C2: SHR-A1811 with BP102Drug
C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
D1: TROP2 ADCDrug
D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
D2: TROP2 ADC with BP102Drug
D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
E1: SHR-A1811Drug
E1: an anti-HER2 antibody-drug conjugate (ADC)
F1: TROP2 ADCDrug
F1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
G1: SHR-A1811Drug
G1: an anti-HER2 antibody-drug conjugate (ADC)
H1: TROP2 ADCDrug
H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
E2: SHR-A1811 with everolimusDrug
E1: SHR-A1811 an anti-HER2 antibody-drug conjugate (ADC) everolimus: an mTOR inhibitor
TQB2102 with TQB2868Drug
TQB2102: an anti-HER2 antibody-drug conjugate (ADC) TQB2868: an anti-PD-1/TGF-β bispecific antibody in all-comer TNBC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 3 years)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.